Due to the reduced efficacy of conventional chemotherapy and the poor prognosis of the full-relapsed B-ALL, the patient was enrolled in an anti-CD19 CART-cell therapy clinical trial (NCT02975687) under informed consent. Here, CD19 is linked to acute lymphoblastic leukemia.